Peace of Mind through Redefined Cancer Survelliance

Matrix-Bio is employing metabolite profiling to create powerful new cancer diagnostic tests that provide an instantaneous snapshot of a patient's metabolism. These tests will detect the presence and
reoccurrence of cancer and monitor treatment with greater accuracy, speed, and less discomfort to the patient than current testing methodologies. We are redefining hope.

VeraMarker-BCR Breast Cancer Test

There are currently 2.5 million breast cancer survivors who may benefit from recurrence monitoring. This new recurrence-monitoring test measures key metabolic changes to quickly and accurately detect the return of cancer.


Investor Ready

Matrix-Bio expects to go to market with the world's first metabolite-based commercial test for breast cancer in 2012. We are currently in the process of raising series A equity.


News

Cancer Research Publishes Matrix-Bio's Study on Detecting Breast Cancer Recurrence
Blood test accurately detected cancer recurrence an average of 13 months before clinical diagnosis.


Your Questions Answered

What is metabolite profiling? How does it benefit breast cancer patients and their physicians?